Cargando…

Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease

This report represents a detailed description of experiments designed to replicate and extend the findings of a published study on the effects of treating the R6/2 Huntington’s disease (HD) mouse model with ~300 CAG repeats using the pimelic diphenylamide histone deacetylase (HDAC) inhibitor, HDACi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jane Y., Wang, Elizabeth A., Galvan, Laurie, Huynh, My, Joshi, Prasad, Cepeda, Carlos, Levine, Michael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Preclinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574864/ https://www.ncbi.nlm.nih.gov/pubmed/23437422 http://dx.doi.org/10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202

Ejemplares similares

Correction: Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease
Publicado: (2017)

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo
por: Beconi, Maria, et al.
Publicado: (2012)

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model
por: Rai, Myriam, et al.
Publicado: (2010)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Case of Pimelitis
por: Gill, Railton
Publicado: (1842)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs)
por: Mackmull, Marie-Therese, et al.
Publicado: (2015)

Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
por: Zhang, Na, et al.
Publicado: (2020)

Acute Kidney Injury Results in Long-Term Diastolic Dysfunction That Is Prevented by Histone Deacetylase Inhibition
por: Soranno, Danielle E., et al.
Publicado: (2021)

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
por: Friedrich, Annabelle, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer
por: Kong, Yanjie, et al.
Publicado: (2022)

Pimelic acid–urea (1/2)
por: Xu, Wei, et al.
Publicado: (2011)

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer
por: Losson, Hélène, et al.
Publicado: (2016)

Targeting Huntington’s disease through histone deacetylases
por: Gray, Steven G.
Publicado: (2011)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Histone Deacetylase 6 (HDAC6) Is an Essential Modifier of Glucocorticoid-Induced Hepatic Gluconeogenesis
por: Winkler, Robin, et al.
Publicado: (2012)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Chromatin remodeling induced by histone deacetylase inhibitors (HDACis) in HeLa, NIH 3T3 and HepG2 cells
por: Felisbino, Marina B, et al.
Publicado: (2013)

Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure
por: Qiu, Xiaodi, et al.
Publicado: (2019)

A transcriptomic dataset used to derive biomarkers of chemically induced histone deacetylase inhibition (HDACi) in human TK6 cells
por: Cho, Eunnara, et al.
Publicado: (2021)

Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington’s Disease1,2,3
por: Holley, Sandra M., et al.
Publicado: (2015)

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
por: Jonsson, Marte, et al.
Publicado: (2016)

Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington’s disease
por: Donley, David W., et al.
Publicado: (2021)

Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington’s disease
por: Stepanova, P., et al.
Publicado: (2023)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington’s disease
por: Islam, Jaisan, et al.
Publicado: (2021)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
por: Arts, J, et al.
Publicado: (2007)

The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington’s Disease Mice
por: Hecklau, Katharina, et al.
Publicado: (2021)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis
por: Klingl, Yvonne E., et al.
Publicado: (2020)

Remarkable Diversity in the Enzymes Catalyzing the Last Step in Synthesis of the Pimelate Moiety of Biotin
por: Shapiro, Madelyn M., et al.
Publicado: (2012)

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice
por: Jia, Haiqun, et al.
Publicado: (2016)

HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013)

Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington’s Disease
por: Jang, Minhee, et al.
Publicado: (2018)

Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells
por: Gnedina, Olga O., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p1tqln8q5l8vmqjerl61ncu5u4